GlassScriptPhysician profile
Dharmesh V Gandhi
NPI 1417949835
$2,873.67
in general payments reported to CMS, 2019-2025
26 companies · $668 in 2025
The $668 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $176 · 2021: $81.86 · 2022: $606 · 2023: $385 · 2024: $668 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658 · Education: $62.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.14 |
| Education | $62.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $517.34 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Ethicon INC. | $455.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $384.13 | 2022-2025 | Libtayo, Dupixent |
| Astrazeneca Pharmaceuticals LP | $271.83 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $164.41 | 2019-2025 | |
| Inspire Medical Systems, INC. | $163.73 | 2023-2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.62 | 2019-2025 | Ofev |
| Lilly USA, LLC | $104.16 | 2019-2025 | Zepbound |
| Insmed, INC. | $90.88 | 2020-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $75.27 | 2023-2025 | Uptravi, Opsynvi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $69.52 | 2022-2024 | Glassia |
| Jazz Pharmaceuticals INC. | $68.87 | 2019-2023 | |
| Abiomed | $54.61 | 2025 | |
| Genentech USA, INC. | $44.48 | 2023 | Xolair |
| Grifols USA, LLC | $35.13 | 2024-2025 | Prolastin-C Liquid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.38 | 2022-2023 | |
| Zoll Respicardia, INC. | $32.94 | 2025 | Remede System |
| Sunovion Pharmaceuticals INC. | $30.23 | 2019 | |
| United Therapeutics Corporation | $21.54 | 2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $19.05 | 2024 | Keytruda |
| Shionogi INC | $18.00 | 2022 | |
| Verona Pharma, INC. | $16.43 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $15.88 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $15.25 | 2024 | Lumryz |
| Inogen, INC. | $14.08 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Mylan Specialty L.P. | $12.91 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharmesh Gandhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.